The clinical profiles that make a supervised trial reasonable include: For Semax: Adults with documented cognitive concerns persistent brain fog, memory complaints, executive dysfunction that have been worked up to rule out reversible causes (thyroid, insulin resistance, B12 deficiency, sleep disorders) Individuals recovering from neurological insult where BDNF upregulation has clinical rationale High-performance adults seeking evidence-informed cognitive support under physician supervision For Selank: Adults with documented anxiety particularly GAD patterns who have had poor tolerability with standard anxiolytics or want to avoid benzodiazepine dependency Individuals experiencing stress-related cognitive impairment: mental fatigue under load, working memory degradation under pressure Patients in whom anxiety and cognitive performance deficits are co-occurring Neither compound should be used: Without a baseline laboratory workup ruling out metabolic drivers of cognitive symptoms (insulin resistance and cognitive function are directly connected see Meto's Insulin Resistance & Prediabetes program for why this baseline matters) During pregnancy or in patients with active psychiatric conditions requiring established pharmacotherapy Without discussion of the current regulatory status and sourcing pathway with a qualified clinician For a complete guide to baseline labs before any peptide protocol, see How to Start Growth Hormone Peptide Therapy: What Labs to Order First the pre-protocol framework applies broadly across peptide classes
Mutagenesis 17 , 471481 (2002)
Available from: 54.Sjstrm L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden , et al
Geller, D
The role of artificial intelligence in identifying depression and anxiety: a comprehensive literature review
